|
1
|
Tsuya A, Kurata T, Tamura K and Fukuoka M:
Skeletal metastases in non-small cell lung cancer: A retrospective
study. Lung Cancer. 57:229–232. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mamon HJ, Yeap BY, Jänne PA, Reblando J,
Shrager S, Jaklitsch MT, Mentzer S, Lukanich JM, Sugarbaker DJ,
Baldini EH, et al: High risk of brain metastases in surgically
staged IIIA non-small-cell lung cancer patients treated with
surgery, chemotherapy, and radiation. J Clin Oncol. 23:1530–1537.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lemjabbar-Alaoui H, Hassan OU, Yang YW and
Buchanan P: Lung cancer: Biology and treatment options. Biochim
Biophys Acta. 1856:189–210. 2015.PubMed/NCBI
|
|
4
|
Owonikoko TK, Arbiser J, Zelnak A, Shu HK,
Shim H, Robin AM, Kalkanis SN, Whitsett TG, Salhia B, Tran NL, et
al: Current approaches to the treatment of metastatic brain
tumours. Nat Rev Clin Oncol. 11:203–222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rossi A, Chiodini P, Sun JM, O'Brien ME,
von Plessen C, Barata F, Park K, Popat S, Bergman B, Parente B, et
al: Six versus fewer planned cycles of first-line platinum-based
chemotherapy for non-small-cell lung cancer: A systematic review
and meta-analysis of individual patient data. Lancet Oncol.
15:1254–1262. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Leon G, MacDonagh L, Finn SP, Cuffe S and
Barr MP: Cancer stem cells in drug resistant lung cancer: Targeting
cell surface markers and signaling pathways. Pharmacol Ther.
158:71–90. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
He X, Tsang TC, Pipes BL, Ablin RJ and
Harris DT: A stem cell fusion model of carcinogenesis. J Exp Ther
Oncol. 5:101–109. 2005.PubMed/NCBI
|
|
9
|
Castillo V, Valenzuela R, Huidobro C,
Contreras HR and Castellon EA: Functional characteristics of cancer
stem cells and their role in drug resistance of prostate cancer.
Int J Oncol. 45:985–994. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu C and Alman BA: Side population cells
in human cancers. Cancer Lett. 268:1–9. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Haraguchi N, Utsunomiya T, Inoue H, Tanaka
F, Mimori K, Barnard GF and Mori M: Characterization of a side
population of cancer cells from human gastrointestinal system. Stem
Cells. 24:506–513. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hirschmann-Jax C, Foster AE, Wulf GG,
Nuchtern JG, Jax TW, Gobel U, Goodell MA and Brenner MK: A distinct
‘side population’ of cells with high drug efflux capacity in human
tumor cells. Proc Natl Acad Sci USA. 101:pp. 14228–14233. 2004;
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fletcher JI, Haber M, Henderson MJ and
Norris MD: ABC transporters in cancer: More than just drug efflux
pumps. Nat Rev Cancer. 10:147–156. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Epstein T, Xu L, Gillies RJ and Gatenby
RA: Separation of metabolic supply and demand: Aerobic glycolysis
as a normal physiological response to fluctuating energetic demands
in the membrane. Cancer Metab. 2:72014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thorne JL and Campbell MJ: Nuclear
receptors and the Warburg effect in cancer. Int J Cancer.
137:1519–1527. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gatenby RA and Gillies RJ: A
microenvironmental model of carcinogenesis. Nat Rev Cancer.
8:56–61. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rich PR: The molecular machinery of
Keilin's respiratory chain. Biochem Soc Trans. 31:1095–1105. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Magder SA: The ups and downs of heart
rate. Crit Care Med. 40:239–245. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao W, Yu H, Han Z, Gao N, Xue J and Wang
Y: Clinical significance of joint detection of serum CEA, SCCA, and
bFGF in the diagnosis of lung cancer. Int J Clin Exp Pathol.
8:9506–9511. 2015.PubMed/NCBI
|
|
20
|
Shaye K, Amir T, Shlomo S and Yechezkel S:
Fasting glucose levels within the high normal range predict
cardiovascular outcome. Am Heart J. 164:111–116. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Frese EM, Fick A and Sadowsky HS: Blood
pressure measurement guidelines for physical therapists. Cardiopulm
Phys Ther J. 22:5–12. 2011.PubMed/NCBI
|
|
22
|
Wu X, Zhao M, Pan B, Zhang J, Peng M, Wang
L, Hao X, Huang X, Mu R, Guo W, et al: Complete blood count
reference intervals for healthy Han Chinese adults. PLoS One.
10:e01196692015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang P, Meng Z, Tan J, Jia Q and Zhang F:
An improved method for measurement of target-to-background ratio in
assessing mediastinal lesions on 18F-FDG coincidence SPECT/CT
imaging. Nucl Med Commun. 31:398–404. 2010.PubMed/NCBI
|
|
24
|
Noebauer-Huhmann IM, Szomolanyi P,
Kronnerwetter C, Widhalm G, Weber M, Nemec S, Juras V, Ladd ME,
Prayer D and Trattnig S: Brain tumours at 7T MRI compared to
3T-contrast effect after half and full standard contrast agent
dose: Initial results. Eur Radiol. 25:106–112. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hsu PP and Sabatini DM: Cancer cell
metabolism: Warburg and beyond. Cell. 134:703–707. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dang CV, Hamaker M, Sun P, Le A and Gao P:
Therapeutic targeting of cancer cell metabolism. J Mol Med (Berl).
89:205–212. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Birsoy K, Sabatini DM and Possemato R:
Untuning the tumor metabolic machine: Targeting cancer metabolism:
A bedside lesson. Nat Med. 18:1022–1023. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rosano C: Molecular model of hexokinase
binding to the outer mitochondrial membrane porin (VDAC1):
Implication for the design of new cancer therapies. Mitochondrion.
11:513–519. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jae HJ, Chung JW, Park HS, Lee MJ, Lee KC,
Kim HC, Yoon JH, Chung H and Park JH: The antitumor effect and
hepatotoxicity of a hexokinase II inhibitor 3-bromopyruvate: In
vivo investigation of intraarterial administration in a rabbit VX2
hepatoma model. Korean J Radiol. 10:596–603. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wallace DC: Mitochondria and cancer:
Warburg addressed. Cold Spring Harb Symp Quant Biol. 70:363–374.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Winquist RJ, Boucher DM, Wood M and Furey
BF: Targeting cancer stem cells for more effective therapies:
Taking out cancer's locomotive engine. Biochem Pharmacol.
78:326–334. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Patchell RA, Tibbs PA, Regine WF, Dempsey
RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA and Young B:
Postoperative radiotherapy in the treatment of single metastases to
the brain: A randomized trial. JAMA. 280:1485–1489. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Patchell RA, Tibbs PA, Walsh JW, Dempsey
RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS and Young
B: A randomized trial of surgery in the treatment of single
metastases to the brain. N Engl J Med. 322:494–500. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Coleman RE: Metastatic bone disease:
Clinical features, pathophysiology and treatment strategies. Cancer
Treat Rev. 27:165–176. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rosen LS, Gordon D, Tchekmedyian S,
Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng
M, Urbanowitz G, et al: Zoledronic acid versus placebo in the
treatment of skeletal metastases in patients with lung cancer and
other solid tumors: A phase III, double-blind, randomized trial -
the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.
J Clin Oncol. 21:3150–3157. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rosen LS, Gordon D, Tchekmedyian NS,
Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng
M, Urbanowitz G, et al: Long-term efficacy and safety of zoledronic
acid in the treatment of skeletal metastases in patients with
nonsmall cell lung carcinoma and other solid tumors: A randomized,
phase III, double-blind, placebo-controlled trial. Cancer.
100:2613–2621. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Masters GA, Temin S, Azzoli CG, Giaccone
G, Baker S Jr, Brahmer JR, Ellis PM, Gajra A, Rackear N, Schiller
JH, et al: American Society of Clinical Oncology Clinical Practice:
Systemic therapy for stage IV non-small-cell lung cancer: American
Society of Clinical Oncology Clinical Practice Guideline Update. J
Clin Oncol. 33:3488–3515. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Belani CP: Optimizing chemotherapy for
advanced non-small cell lung cancer: Focus on docetaxel. Lung
Cancer. 50 Suppl 2:3–8. 2005. View Article : Google Scholar
|
|
39
|
Gross GE, Boldt DH and Osborne CK:
Perturbation by insulin of human breast cancer cell cycle kinetics.
Cancer Res. 44:3570–3575. 1984.PubMed/NCBI
|
|
40
|
Oster JB and Creasey WA: Enhancement of
cellular uptake of ellipticine by insulin preincubation. Eur J
Cancer Clin Oncol. 17:1097–1103. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Alabaster O, Vonderhaar BK and Shafie SM:
Metabolic modification by insulin enhances methotrexate
cytotoxicity in MCF-7 human breast cancer cells. Eur J Cancer Clin
Oncol. 17:1223–1228. 1981. View Article : Google Scholar : PubMed/NCBI
|
